Vanguard Capital Management’s Celldex Therapeutics CLDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$113M Buy
3,476,055
+11,224
+0.3% +$429K ﹤0.01% 1460
2026
Q2
$129M Buy
3,464,831
+503,936
+17% +$16.3M ﹤0.01% 1422
2026
Q1
$93.9M Buy
+2,960,895
New +$80.7M ﹤0.01% 1504

Other funds holding CLDX

Vanguard Capital Management's CLDX Position: Q3 2026 in Review

Vanguard Capital Management increased its Celldex Therapeutics (CLDX) stake by 0.32% in Q3 2026, buying an estimated $429K and bringing the position to 3,476,055 shares worth $113M. The position accounts for ﹤0.01% of the portfolio, ranked #1460.

Vanguard Capital Management first reported a position in CLDX in Q1 2026 and has held it in 3 quarters since. The position peaked at $129M in Q2 2026. 249 funds tracked by Wall St. Rank hold CLDX as of Q3 2026.

  • Vanguard Capital Management held 3,476,055 shares of Celldex Therapeutics worth $113M as of Q3 2026.
  • Vanguard Capital Management bought 11,224 Celldex Therapeutics shares in Q3 2026, an estimated $429K.
  • Celldex Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #1460 holding.
  • Vanguard Capital Management first reported a position in Celldex Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Capital Management's Celldex Therapeutics position peaked at $129M in Q2 2026.
  • 249 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.